Kamada (NASDAQ:KMDA) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.39 and traded as low as $5.31. Kamada shares last traded at $5.34, with a volume of 19,941 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KMDA shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Thursday, August 15th. Stifel Nicolaus started coverage on Kamada in a research note on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price target for the company. Finally, StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Kamada Stock Performance

The company has a 50-day moving average of $5.41 and a 200-day moving average of $5.39. The stock has a market capitalization of $303.49 million, a price-to-earnings ratio of 19.56 and a beta of 1.06.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $39.70 million. Kamada had a return on equity of 6.15% and a net margin of 9.75%. As a group, analysts expect that Kamada Ltd. will post 0.26 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kamada stock. Vanguard Group Inc. grew its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 8.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,325,026 shares of the biotechnology company’s stock after buying an additional 100,800 shares during the period. Vanguard Group Inc. owned 2.31% of Kamada worth $7,433,000 as of its most recent SEC filing. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.